Skip to main content

Table 1 Baseline characteristics of cases and controls

From: Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline

Parameter

Cases (n = 19)

Controls (n = 20)

P value

Agea

27.3 (6.2)

27.1 (5.6)

.9

Gender (men:women)

1:18

2:18

 

Body weight (kg)a

57.3 (9.5)

60.3 (11.1)

.35

BMI (kg/m2)a

24.2 (4.0)

24.6 (3.9)

.73

Waist (cm)a

85.3 (12.0)

83.3 (7.4)

.52

Hip (cm)a

91.1 (8.7)

91.4 (9.0)

.91

Waist–hip ratioa

0.94 (0.12)

0.92 (0.09)

.68

Body fat (kg)

23.4 (10.4)

20.5 (8.3)

.69

Trunk fat (kg)a

11.0 (4.2)

9.3 (2.8)

.044

Fasting glucose (mmol/l)a

4.8 (0.5)

4.2 (0.3)

<.001

Fasting insulin (pmol/l)

34.3 (54.6)

35.9 (22.3)

.82

HOMA-IR

1.1 (1.27)

1.4 (0.59)

.64

Total cholesterol (mmol/l)

4.5 (1.4)

3.4 (1.6)

.02

LDL (mmol/l)a

2.9 (0.8)

2.1 (0.5)

.001

HDL (mmol/l)

1.1 (0.3)

1.2 (0.3)

.04

Triglycerides (mmol/l)a

1.8 (0.4)

1.4 (0.4)

.009

Uric acid (µmol/l)a

297.9 (66.6)

206.9 (75.5)

<.001

FSH (IU/l)a

5.7 (2.6)

5.8 (1.8)

.88

LH (IU/l)a

5.3 (4.4)

5.2 (1.5)

.96

Estradiol (pg/ml)a

52.7 (24.3)

85.7 (42.6)

.018

  1. HOMA-IR homeostatic model of insulin resistance, LDL low density lipoprotein cholesterol, HDL high density lipoprotein cholesterol
  2. aNormally distributed data are expressed as mean (SD). Other data (non-normally distributed) expressed as median (interquartile range)